Notably, under gefitinib treatment, NSCLC cells in the control group exhibited higher survival rate that those in LANCL1-AS1-overexpressed group, indicating that LANCL1-AS1 promoted NSCLC cell sensitivity to gefitinib (Figure 2b). The gene discussed is LANCL1; the disease is non-small cell lung carcinoma.